# Ablative Solutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ablative-solutions

- Industry: Medical Devices & Equipment
- Headquarters: Wakefield, US
- Website: www.ablativesolutions.com
- Total disclosed funding: $74M
- Latest round: Series D (Feb 1, 2021)
- Investors on record: 6

## About

Ablative Solutions, Inc. is a medical technology company focused on developing innovative treatments for hypertension, with an emphasis on their flagship Peregrine System that utilizes advanced renal denervation techniques.Ablative Solutions, Inc., founded in 2011 and headquartered in Wakefield, US, specializes in medical solutions for hypertension. The company has raised a total of USD 37.00 mn in funding, with the most recent Series D round occurring on February 1, 2021. The funding was supported by investors including BioStar Capital, Gilde Healthcare Partners, and Invus. The CEO, Kate Rumrill, leads the company but there are no mentions of prior companies founded by her.Ablative Solutions, Inc. specializes in the development of innovative medical solutions aimed at addressing hypertension through its flagship product, the Peregrine System. This investigational product employs an alcohol-mediated renal denervation approach to effectively reduce high blood pressure in patients suffering from uncontrolled hypertension. The Peregrine System is currently under clinical trial evaluation, focused on assessing its safety and efficacy in a clinical setting. The primary end users of this technology are healthcare providers and their patients, particularly those who have not responded adequately to traditional hypertension treatments. Ablative Solutions' products are primarily marketed within the United States, although there may be international interests in the technology as research progresses.The revenue model of Ablative Solutions, Inc. is centered around the clinical trial and investigational use of its Peregrine System Kit, which is not yet commercially available. Transactions are structured around partnerships with healthcare institutions and clinical research organizations to facilitate the trials necessary for product validation. As the Peregrine System is still in the evaluation phase, specific pricing plans and financial arrangements have not been disclosed, but the company is likely focused on securing collaborations that may lead to future commercialization.In February 2021, Ablative Solutions, Inc. raised USD 37.00 mn in Series D funding to support its initiatives. The company plans to leverage this funding to advance the development of the Peregrine System and prepare for potential commercialization upon successful clinical trial outcomes. Future growth may include expanding into international markets where there is a demand for hypertension treatments, although specific regions have not been detailed. Ablative Solutions is strategically positioned to enhance its product offerings as it completes clinical evaluations.

## Funding rounds

- Series D, Feb 1, 2021, $37M — Gilde Healthcare, BioStar Capital, Invus [DUP]
- Series D, Dec 28, 2018, $17M — Gilde Healthcare, BioStar Capital, Novus Biologicals, Charter Capital Partners
- Series B, Jan 12, 2015, $0.3M — BioStar Capital, Michigan Accelerator Fund
- Series B, Oct 22, 2014, $4.7M — BioStar Capital
- Series B, Dec 30, 2013, $9.6M — BioStar Capital, Charter Capital Partners
- Series A, Jun 14, 2012, $5.4M — BioStar Capital, Charter Capital Partners

## Investors

- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series A, Series B, Series D
- Charter Capital Partners (https://capitalatlas.ai/funds/charter-capital-partners) — Series A, Series B, Series D
- Michigan Accelerator Fund — Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series D
- Novus Biologicals — Series D
- Invus [DUP] — Series D